New Confirmed Delegates & Speakers for RNA Therapeutics
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led Arrowhead’s acquisition of the Novartis RNAi assets and led Arrowhead’s $670 Million cardiovascular deal with Amgen. Dr. Hamilton previously served as CEO of Calando Pharmaceuticals. He earned an MD and MBA at The Ohio State University and is board certified in Emergency Medicine.
We had the chance to interview Dr. Hamilton about his background and career experience.
Below is a snapshot of his interview:
Q. What do you believe are the biggest challenges associated with developing an RNA Therapeutic?
A. Identification of novel targets that can be modulated with available delivery technologies.
Q. What lessons can be learnt following several years of RNA-based therapeutic development?
A. Scientific endeavors such as the development of a new therapeutic class will inevitably be met with breakthroughs and setbacks. Learning from one’s mistakes and persistence are key.
Check out the full interview, available in the download centre. www.therapeutics-rna.com/opr
Hear more from Dr. James Hamilton at RNA Therapeutics this February 2018, as he presents 'The Evolution of RNAi Delivery at Arrowhead'.
RNA Interference is used to silence genes before it produces the protein, which is harmful for the body. However, in order for this to be effective, ways to safely and effectively deliver this therapeutic to its target must also be developed. Arrowhead Pharmaceuticals is one of the companies leading this search. This presentation will cover the previous technologies Arrowhead have used, analyse the changes that have been made to improve the technologies and look at the potential of Arrowhead’s current synthetic siRNA delivery systems including dynamic PolyConjugates.
Topics will explore:
- Older RNAi delivery technologies
- Dynamic Polyconjugates: Pre-clinical and Clinical Experience
- Arrowhead Single Molecule RNAi Conjugates
Latest Confirmed Delegates:
Evonik Nutrition & Care GmbH | Heptares Therapeutics | N4 Pharma UK Limited | The Italian Institute of Technology | University Of Twente / 20Med
For those looking to attend there is currently a £400 early-bird saving, ending October 31st
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
1 Westminster Bridge Rd, London SE1 7XW
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Confirmed Delegates & Speakers for RNA Therapeutics here
News-ID: 788669 • Views: 1598
More Releases from SMi Group
Navigating the challenges and legal landscapes of parallel trade
Book to attend the Parallel Trade conference before midnight Friday 28 th January and save £100 SMi Presents the 16th Annual Conference: Parallel Trade 2022 Conference Date: 21st – 22nd March 2022 Workshop date: 23rd March 2022 Website: www.parallel-trade.com/ Navigating the challenges and legal landscapes of parallel trade SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides
Invitation from Conference Chairman, Jeremy Heath, Sutton & East Surrey Water fo …
Building on the success of previous years, SMi’s 11th Annual Smart Water Systems Conference will offer peer-to-peer networking with leaders in the Smart Water Market give delegates in depth knowledge on the requirements you need to build an efficient Advanced Metering Infrastructure. The conference will convene on 4th and 5th April 2022 in London, UK, interested parties can register at http://www.smart-water-systems.com/PR2openPR - register by 31st January 2022 to save £200. The aim
New speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join 3D …
SMi Group reports: new speakers from Abbvie, GSK, Scripps Research and Engitix Therapeutics join the 5th Annual 3D Cell Culture Conference in February 2022 Only four weeks to go until the 5th Annual 3D Cell Culture will now take place as a ‘Virtual Conference’ with online access only on 9th and 10th February 2022. Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to
Registration is now open for Highly Potent Active Pharmaceutical Ingredients 202 …
SMi Group reports: The 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference is set to return in May 2022 with a focus on key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies. SMi Group is delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference, taking place on the 9th and 10th May 2022 in London, UK. The 2022 Conference theme is ensuring product quality
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
DNA/RNA Extraction Equipment Market: Competitive Dynamics & Global Outlook 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global DNA/RNA Extraction Equipment market. Robotic liquid handling technology in automated DNA extraction systems can streamline the tasks involved in extracting DNA from a sample, such as serial dilution and cherry picking. Systems typically also include functions such as shaking, temperature control, and PCR protocols. DNA extraction is used in many types of biological research including molecular
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and
Special student rate for RNA Nanotechnology conference
Fusion Conferences and the Chairs of RNA Nanotechnology have introduced a Special Student Rate for their conference on 01-04 August 2016. The conference, to be held at Wokefield Park in Berkshire, UK, sold out earlier this month with registrations being closed off to the public, but Fusion have opened up some spaces to allow students to enjoy the conference at a discounted rate. Dr. Peixuan Guo of Ohio State University and one